Plant-derived exosome-like nanovesicles alleviate testicular injury by suppressing p21-mediated cell cycle arrest in Sertoli cells
Summary
Testicular dysfunction represents a leading cause of male infertility, yet effective therapeutic interventions remain elusive. Here, we report a novel plant-derived nanotherapeutic strategy for testicular injury using Cistanche deserticola-derived exosome-like nanovesicles (CDELNs).
Keywords
Testicular dysfunction represents a leading cause of male infertility, yet effective therapeutic interventions remain elusive. Here, we report a novel plant-derived nanotherapeutic strategy for testicular injury using Cistanche deserticola-derived exosome-like nanovesicles (CDELNs). CDELNs are preferentially internalized by testicular Sertoli cells via heparan sulfate proteoglycan (HSPG)-mediated endocytosis, whereupon, CDELN-derived miR-159b-3p directly targets the 3'UTR of Cdkn1a mRNA, leading to downregulation of p21 and subsequent alleviation of p21-mediated cell cycle arrest in Sertoli cells. In a mouse model of testicular injury, administration of CDELNs significantly ameliorated testicular histopathology, restored blood-testis barrier integrity, improved sperm quality and key hormone levels, and partially rescued fertility. Notably, reanalysis of publicly available single-cell RNA-seq data from non-obstructive azoospermia (NOA) patients revealed elevated CDKN1A expression in Sertoli cells, suggesting that p21 dysregulation may also contribute to human testicular dysfunction. In summary, our study supports CDELNs as a natural nanovesicle-based candidate that protects against testicular injury through miRNA-mediated p21 suppression, offering a promising translational avenue for male infertility.
Abstract from PubMed (PMID 42989243). This entry was added automatically by our daily literature monitor because it matches the topics we follow; read the full paper at the original source.
Related articles
Let's engineer the next delivery breakthrough together
We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
